Diffuse glioma
Conditions
Interventions
FGFR3-altered group:None
Non FGFR3-altered group:None
Sponsors
The First Affiliated Hospital of Army Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. aged more than 18-year old, with any gender; 2. Newly diagnosed and recurrent glioma patients who have undergone surgical treatment at our hospital. The pathology diagnosis is confirmed as glioblastoma, high-grade glioma, diffuse glioma NOS (not otherwise specified), or diffuse glioma NEC (not elsewhere classified), with a WHO grade of 2-4; 3. Molecular pathology test results has been completed or sufficient samples stored in our hospital's biobank for molecular pathology testing; 4. Molecular pathology test results show no IDH mutations and no EGFR copy number amplification or EGFRvIII mutations; 5. Participants voluntarily cooperate with follow-up;
Exclusion criteria
Exclusion criteria: 1. Cases that have only undergone biopsy or have already received treatment with corticosteroids; 2. Cases with revised pathological diagnoses of circumscribed gliomas, glioneuronal and neuronal tumors, or ependymomas, as well as cases with indeterminate diagnoses; 3. Molecular pathology tests indicate histone H3-related gene alterations or other features of RTK signaling pathway alterations, such as NTRK, ROS1, ALK, and MET fusions. 4. Restored samples do not meet the testing requirements of this project; 5. Previous physical or mental conditions that could affect the follow-up, or concurrent other malignant tumors;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Death(2 year Overall Survival); | — |
Secondary
| Measure | Time frame |
|---|---|
| Tumor recurrence confirmed by radiology(Recurrence-free survival, RFS); | — |
Countries
China
Contacts
Public ContactYu Shi
The First Affiliated Hospital of Army Medical University
Outcome results
None listed